Niv Edward Caviar
Vorstandsvorsitzender bei SpineOvations, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Neville Alleyne | M | - |
SpineOvations, Inc.
SpineOvations, Inc. Medical SpecialtiesHealth Technology SpineOvations, Inc. operates as a clinical-stage medical device company. It develops therapies to treat low back pain. The company was founded by Neville Alleyne and is headquartered in Carlsbad, CA. | - |
William J. Nydam | M | - |
SpineOvations, Inc.
SpineOvations, Inc. Medical SpecialtiesHealth Technology SpineOvations, Inc. operates as a clinical-stage medical device company. It develops therapies to treat low back pain. The company was founded by Neville Alleyne and is headquartered in Carlsbad, CA. | - |
Marc Bellotti | M | - |
SpineOvations, Inc.
SpineOvations, Inc. Medical SpecialtiesHealth Technology SpineOvations, Inc. operates as a clinical-stage medical device company. It develops therapies to treat low back pain. The company was founded by Neville Alleyne and is headquartered in Carlsbad, CA. | - |
William R. Taylor | M | - |
SpineOvations, Inc.
SpineOvations, Inc. Medical SpecialtiesHealth Technology SpineOvations, Inc. operates as a clinical-stage medical device company. It develops therapies to treat low back pain. The company was founded by Neville Alleyne and is headquartered in Carlsbad, CA. | - |
Stuart Young | M | - |
SpineOvations, Inc.
SpineOvations, Inc. Medical SpecialtiesHealth Technology SpineOvations, Inc. operates as a clinical-stage medical device company. It develops therapies to treat low back pain. The company was founded by Neville Alleyne and is headquartered in Carlsbad, CA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Vivid Sehgal | M | 56 | 8 Jahre | |
Abhay Joshi | M | 61 | 5 Jahre | |
Caroline F. van Hove | F | 43 | 16 Jahre | |
William Humphries | M | 57 | 8 Jahre | |
Charles McDermott | M | 52 | 8 Jahre | |
Aimee Weisner | F | 55 | 4 Jahre | |
Stephen J. Ryan | M | 83 | 11 Jahre | |
Russ Ray | M | 77 | 12 Jahre | |
Sanjiv Patel | M | 50 | 11 Jahre | |
Louis Lavigne | M | 75 | 10 Jahre | |
Robert Alexander Ingram | M | 81 | 7 Jahre | |
Eric Brandt | M | 62 | 6 Jahre | |
David Hollander | M | 50 | - | |
Les Kaplan | M | 73 | 21 Jahre | |
Deborah Dunsire | M | 61 | 9 Jahre | |
Trevor Jones | M | 82 | 11 Jahre | |
Louis T. Rosso | M | - | 16 Jahre | |
Roy J. Wilson | M | 68 | - | |
Christian Henry | M | 56 | 4 Jahre | |
Paul Little | M | 60 | 12 Jahre | |
Crystal Muilenburg | F | 45 | 11 Jahre | |
Lisa D. Parr | M | 59 | 3 Jahre | |
Pat Brooks | M | - | - | |
Lori Lyons-Williams | F | 46 | 14 Jahre | |
Karen Potts | M | 61 | 3 Jahre | |
Jamie Kole | F | - | 7 Jahre | |
Sesha Neervannan | M | 56 | 13 Jahre | |
Alan Williams | M | - | - | |
Grace Colón | M | 57 | 5 Jahre | |
Richard P. M. Glover | M | 57 | 5 Jahre | |
William F. Daly | M | - | 2 Jahre | |
Frederick C. Beddingfield | M | 59 | - | |
Janice Drew | F | - | - | |
Paul L. Jenkinson | M | 64 | 9 Jahre | |
Aziz Mottiwala | M | 46 | 11 Jahre | |
Robert T. Joseph | M | 47 | 2 Jahre | |
Gary Charbonneau | M | - | 11 Jahre | |
Michael Sherman | M | - |
iTherX Pharmaceuticals, Inc.
iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | 2 Jahre |
Ian Bell | M | 54 | 9 Jahre | |
Dennis Huang | M | 59 | 7 Jahre | |
Vickie Motte | F | - | 3 Jahre | |
David F. Power | M | - | 18 Jahre | |
Peter A. Kresel | M | 80 | - | |
Cyrus Harmon | M | 53 | 2 Jahre | |
Jacqueline J. Schiavo | F | 75 | 25 Jahre | |
James Barlow | M | 65 | 13 Jahre | |
Kirk McMullin | M | 70 | 7 Jahre | |
Lauren Silvernail | F | 65 | 8 Jahre | |
Patricia Walker | M | 64 | 1 Jahre | |
Josefina T. Elchico | F | 77 | 5 Jahre | |
Brian Culley | M | 53 |
iTherX Pharmaceuticals, Inc.
iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | 2 Jahre |
Matthias C. Kurth | M | 68 | - | |
Karen Osar | F | 74 | 7 Jahre | |
Kenneth J. Nussbacher | M | 70 | 5 Jahre | |
Ronald D. Verdoorn | M | 74 | 3 Jahre | |
Holger Heidrich | M | 71 | 4 Jahre | |
John Kent | M | - | 12 Jahre | |
Thomas A. Mitro | M | 66 | 22 Jahre | |
Joan M. Robbins | M | 63 |
iTherX Pharmaceuticals, Inc.
iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus. | 7 Jahre |
Nader Naini | M | - | 3 Jahre | |
Dennis Podlesak | M | 66 | 4 Jahre | |
Michael J. B. Tansey | M | 75 | 3 Jahre | |
Patrick O'Brien | M | - | 2 Jahre | |
James R. Largent | M | 74 | 6 Jahre | |
George Lasezkay | M | 72 | 13 Jahre | |
Rosh Chandraratna | M | 75 | 20 Jahre | |
Jean Montagu | M | - | 3 Jahre | |
Balbir S. Brar | M | 87 | 13 Jahre | |
Deepak Chadha | M | 54 | 7 Jahre | |
Alan Williams | M | - | 10 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 75 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Niv Edward Caviar
- Persönliches Netzwerk